BioEnterprise Adds Two to Business Development Team.

CLEVELAND -- BioEnterprise Corporation has announced two new key appointments to its staff. The Cleveland developer of bioscience companies named both Glen Gaughan and Michael Lang to its Business Development team.

Michael Lang will lead the company's efforts for advising and evaluating medical device and equipment companies. Lang brings over 20 years of business and product development experience in medical devices. He has played key roles in the initiation of five new business entities including new businesses of Johnson & Johnson and Avery Dennison as well as several startups. Most recently, Lang was General Manager for Avery Dennison's Medical & Microreplication businesses.

Lang has experience in all aspects of the medical device industry, including product development, marketing, business development and general management. He has successfully developed and commercialized a wide array of medical devices, including implants, biomaterials, catheters, imaging, specialty instrumentation, and minimally invasive products in orthopedic, cardiovascular, neurological and general surgery markets. In addition, he brings significant transactional experience in technology licensing, joint ventures and acquisitions. Lang received his B.S. in Bioengineering from Northern Arizona University and received his M.B.A. from Arizona State University.

Glen Gaughan will focus his work at BioEnterprise primarily on biopharmaceutical, drug delivery, and diagnostics opportunities. He is working closely with Arteriocyte, Vascular Biogenics, and Copernicus Therapeutics, supporting the development of their business strategies and product development plans.

Gaughan has almost 20 years of experience as a drug discovery scientist with Bristol-Myers Squibb. In roles ranging from Principal Investigator to Group Leader, he contributed to programs searching for new medications for pain, obesity, sleep disorders, depression, and for contrast agents for MRI. He has extensive laboratory expertise in both chemistry and molecular biology, a thorough understanding of all aspects of the drug discovery and development process, and research group and project management experience. Gaughan designed ProHance, an MRI contrast agent marketed by Bracco. Gaughan holds a Ph.D. in Chemistry from the University of Oregon, an MBA from Case Weatherhead School of Business, and a B.A. from Dartmouth College.

"We're pleased to attract talent of this caliber to BioEnterprise," said BioEnterprise President Baiju R. Shah. "Their breadth of experience adds significant value for our clients, and they will also be very helpful in identifying future clients. Their skills in business and product development, and their knowledge areas in medical devices and biopharmaceuticals, complements the rest of BioEnterprise's business development group. We are excited to have them as part of our team."

Shah noted that while Cleveland is known for its medical device and equipment companies, especially in medical imaging, there is an untapped opportunity to form biopharmaceutical companies based on NIH-funded work at the region's research institutions.

About BioEnterprise Corporation

BioEnterprise Corporation is a business formation, recruitment, and acceleration company committed to supporting the growth of bioscience companies. BioEnterprise provides mission-critical senior management and support services to early stage and emerging growth companies. The BioEnterprise management team is comprised of executives with extensive experience in growing bioscience and technology companies.

Located in Cleveland, Ohio, its founders and equal partners are Case Western Reserve University, The Cleveland Clinic Foundation, and University Hospitals Health System, Inc. Additional regional technology partners include the NASA Glenn Research Center, Cleveland State University, and NorTech.